Emerging Companies

Ron Cohen MD, President and Chief Executive Officer, Acorda Therapeutics, Inc., discusses what is necessary to create an environment of biotech innovation.

BIO featured Jan Lundberg of Eli Lilly as this year's fireside chat speaker at the BIO Investor Forum!

Stephan Tanda, Managing Board Member with Royal DSM, discusses what is necessary to create an environment of biotech innovation.

More than 40 biotech companies have gone public using provisions made available to emerging growth companies through the JOBS Act. BIOtechNOW’s JOBS Act Deconstructed series explores why it has had such an impact on biotech offerings and how emerging companies can leverage the new law to their best advantage.

The Jumpstart Our Business Startups (JOBS) Act was signed into law by President Obama on April 5, 2012. The law mandated certain changes to Rule 506 of SEC Regulation D designed to spur capital formation for growing innovators. The required Regulation D reforms took effect on September 23, 2013, after being finalized by the SEC this summer. A summary of these changes is outlined below.

Since the 2012 signing of the Jumpstart Our Business Startups Act (JOBS Act), many small businesses in the biotech community have benefited from the JOBS Act by being able to focus on research and development rather than onerous and burdensome regulations.

The fifth annual edition of Scientific American Worldview explores ongoing challenges and opportunities in the biopharmaceutical industry, including the looming potential of an “innovation cliff.”

Rob Wright, chief editor of Life Science Leader, previews the “What Does Diversity Mean in the 21st Century?” panel he will be moderating at the Diversity, Inclusion, and Life Sciences Symposium Monday, April 22 in Chicago, Ill.

Recently BIO hosted the 15th annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. The conference is the largest investor conference focused on for established and emerging publicly traded and select private biotech companies.

From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013.

From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013.

From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013.

Fred Frank, formerly Vice Chairman of both Lehman Brothers Inc. and Peter J. Solomon Company, recently became Vice Chairman of Burrill & Company and Chairman of Burrill Securities, the broker dealer arm of Burrill & Company. He was the first life sciences specialist in investment banking, and the most prolific.

The biosimilars pathway is critical for China's biotechnology industry – and this is evident in the investment the government is making in the manufacture of biotech products

April 29 2014
Chairperson Mikulski, Ranking Member Shelby, Members of the Committee, thank you for the opportunity to provide you with written testimony on the extremely important topic of driving innovation through federal investments.
November 6 2013
On behalf of the BIO and its 1,100 members, I am writing in strong support of your Start-up Jobs and Innovation Act. I want to thank you for introducing this important legislation, which will spur investment in small biotech companies and other innovative businesses.
July 10 2013
A healthy public market is key to the success of the biotech industry, as growing innovators often turn to an IPO to fund late-stage clinical trials.
July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.
March 16 2012
On behalf of BIO and its more than 1,100 members, Jim Greenwood submitted a letter to Senate Majority Leader Harry Reid and Minority Leader Mitch McConnell in strong support of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act.
May 9 2014
Bill would strengthen, make permanent critical R&D tax credit
April 9 2014
The House Subcommittee on Capital Markets and Government Sponsored Enterprises held a hearing titled “Legislative Proposals to Enhance Capital Formation for Small and Emerging Growth Companies.” Brian Hahn, Chief Financial Officer of GlycoMimetics, Inc. presented testimony at the hearing on enhancements to the capital markets that can increase access to investors and decrease unnecessary regulatory burdens for emerging biotech companies trading on the public market.
April 7 2014
The EXPIRE Act would extend tax credits that expired at the end of 2013, including several of importance to the biotechnology industry.
February 12 2014
Bill would spur capital formation for small public companies